How does anti-IL-6 receptor monoclonal antibody tocilizumab treatment ameliorate neuromyelitis optica?

被引：0
|
作者：
Matsuoka, T. [1 ,2 ,3 ]
Araki, M. [4 ]
Yamaguchi, H. [1 ]
Sato, W. [1 ]
Miyamoto, K. [5 ]
Kusunoki, S. [5 ]
Gold, R. [6 ]
Yamamura, T. [1 ,4 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Natl Inst Neurosci, Dept Immunol,Natl Ctr Neurol & Psychiat, Tokyo, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Dev Med Sci, Tokyo, Japan
[3] Natl Ctr Neurol & Psychiat, Tokyo Metropolitan Inst Neurosci, Child Brain Project, Tokyo, Japan
[4] Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Multiple Sclerosis Ctr, Tokyo, Japan
[5] Kindai Univ, Dept Neurol, Fac Med, Osaka, Japan
[6] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1755
引用
收藏
页码：1000 / 1001
页数：2
相关论文
共 50 条
  • [21] Long-term safety and efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy, in patients with rheumatoid arthritis
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 122 - 122
  • [22] Treatment of Crohn's disease with anti-IL-6 receptor antibody
    Ito, H
    JOURNAL OF GASTROENTEROLOGY, 2005, 40 (Suppl 16) : 32 - 34
  • [23] Treatment of Crohn’s disease with anti-IL-6 receptor antibody
    Hiroaki Ito
    Journal of Gastroenterology, 2005, 40 : 32 - 34
  • [24] The effect of Neuromyelitis optica (NMO)-IgG and anti-IL-6 receptor monoclonal antibody (SA237; satralizumab) for barrier function at the Blood-Brain Barrier in vitro
    Takeshita, Y.
    Serizawa, K.
    Fujikawa, S.
    Shimizu, F.
    Maeda, T.
    Sano, Y.
    Koga, M.
    Kanda, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 208 - 209
  • [25] Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody; in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis.
    Imagawa, Tomoyuki
    Mori, Masaaki
    Takei, Syuji
    Kawano, Yoshifumi
    Iwata, Naomi
    Miyoshi, Mari
    Murata, Takuji
    Nishimoto, Norihiro
    Kishimoto, Tadamitsu
    Yokota, Shumpei
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S168 - S168
  • [26] Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy
    Lotan, Itay
    McGowan, Richard
    Levy, Michael
    CURRENT NEUROPHARMACOLOGY, 2021, 19 (02) : 220 - 232
  • [27] A humanized anti-IL-6 receptor antibody for the treatment of chronic inflammatory diseases
    Yoshizaki, K.
    Nakazawa, S.
    Nishikawa, T.
    Tanigawa, M.
    Ito, H.
    CYTOKINE, 2012, 59 (03) : 571 - 571
  • [28] Anti-IL-6 receptor antibody therapy for autoimmune diseases
    Ishikawa, N. Nishimoto.
    Lee, H.
    Aoki, C.
    Mima, T.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2009, 301 (01) : 44 - 44
  • [29] Effects of anti-IL-6 receptor antibody on human monocytes
    Tono, Toshihiro
    Aihara, Satoko
    Hoshiyama, Takayuki
    Arinuma, Yoshiyuki
    Nagai, Tatsuo
    Hirohata, Shunsei
    MODERN RHEUMATOLOGY, 2015, 25 (01) : 79 - 84
  • [30] Potential benefits of the anti-IL-6 receptor antibody tocilizumab in multiple sclerosis patients with high plasmablast frequency
    Araki, M.
    Nakamura, M.
    Sato, W.
    Takahashi, Y.
    Yamamura, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 131 - 131
12345